Evaluation of targeted alpha-therapy on patient-derived Glioblastoma cells

Glioblastoma multiforme (GBM) is the deadliest form of human brain tumors, systematically recurring despite multimodal treatment. As a consequence, the average patient survival is less than 15 months, and is thought to be linked with the presence of brain tumor stem cells (BTSCs) that are implicated in treatment resistance. GBM BTSCs are radiotherapy and chemotherapy […]

Read More